Table 2 Descriptive of characteristics of IDS-TILDA participants (n = 677) and of the two physical function measures (grip strength n = 437; TUG n = 468) and representativeness

Total N

677

437

p

468

p

Gender

n = 677

n = 437

0.355

n = 468

0.432

 Male

43.9 (40.2–47.6) (n = 297)

42.6 (37.9–47.4) (n = 186)

44.9 (40.3–49.5) (n = 210)

 Female

56.1 (52.4–59.8) (n = 380)

57.4 (52.6–62.1) (n = 251)

55.1 (50.5–59.7) (n = 258)

Age range

n = 676

n = 437

0.498

n = 468

0.040*

 44–49 years

27.6 (24.2–31.0) (n = 187)

26.5 (22.5–30.9) (n = 116)

28.2 (24.2–32.5) (n = 132)

 50–64 years

51.3 (47.5–55.1) (n = 347)

51.3 (46.5–56.0) (n = 224)

53.4 (48.8–58.0) (n = 250)

 65 years +

21.0 (17.9–24.1) (n = 142)

22.2 (18.4–26.4) (n = 97)

18.4 (15.0–22.2) (n = 86)

Level of ID

n = 624

n = 398

< 0.001*

n = 432

< 0.001*

 Mild

23.9 (20.6–27.3) (n = 149)

30.2 (25.7–34.9) (n = 120)^a

26.4 (22.3–30.8) (n = 114)

 Moderate

44.0 (40.1–47.9) (n = 287)

53.3 (48.2–58.3) (n = 212)^a

49.5 (44.7–54.4) (n = 214)^a

 Severe/Profound

30.1 (26.5–33.7) (n = 188)

16.6 (13.1–20.6) (n = 66)^b

24.1 (20.1–28.4) (n = 104)^b

Type of residence

n = 676

n = 437

< 0.001*

n = 468

0.001*

 Independent

15.0 (12.3–17.7) (n = 102)

17.6 (14.2–21.5) (n = 77)

15.8 (12.6–19.4) (n = 74)

 Community Group Home

44.1 (40.4–47.8) (n = 298)

47.6 (42.8–52.4) (n = 208)

47.9 (43.3–52.5) (n = 224)^a

 Residential Care

40.8 (37.1–44.5) (n = 276)

34.8 (30.3–39.5) (n = 152)^b

36.3 (32.0–40.9) (n = 170)^b

Down syndrome

n = 663

n = 437

0.087

n = 468

0.388

 Yes

19.2 (16.2–22.4) (n = 127)

16.7 (13.3–20.5) (n = 73)

17.3 (14.0–21.0) (n = 81)

 No

80.8 (77.6–83.8) (n = 536)

81.5 (77.5–85.0) (n = 356)

81.0 (77.1–84.4) (n = 379)

Physical activity level

n = 668

n = 432

0.043*

n = 462

0.002*

 Low

73.5 (70.0–76.8) (n = 491)

70.6 (66.1–74.9) (n = 305)

69.5 (65.1–73.7) (n = 321)^b

 Moderate

24.3 (21.0–27.7) (n = 162)

27.3 (23.2–31.8) (n = 118)

28.1 (24.1–32.5) (n = 130)^a

 High

2.2 (1.3–3.7) (n = 15)

2.1 (1.0–3.9) (n = 9)

2.4 (1.2–4.2) (n = 11)

Exposure to any medications

95.1 (93.5–96.7) (n = 644)

93.8 (91.1–95.9) (n = 410)

0.249

94.2 (91.7–96.2) (n = 441)

0.475

Exposure to DBI medications

78.6 (75.5–81.7) (n = 532)

75.3 (71.0–79.3) (n = 329)^b

0.003*

76.7 (72.6–80.5) (n = 359)

0.045*

DBI score

n = 677

n = 437

0.017*

n = 468

0.062

 0

21.4 (18.3–24.5) (n = 145)

24.7 (20.7–29.0) (n = 108)^a

23.3 (19.5–27.4) (n = 109)

 0.1 > 1

24.4 (21.2–27.6) (n = 165)

23.8 (19.9–28.1) (n = 104)

25.4 (21.5–29.6) (n = 119)

  ≥ 1

54.2 (50.5–58.0) (n = 367)

51.5 (46.7–56.3) (n = 225)

51.3 (46.7–55.9) (n = 240)

DBA score

n = 677

n = 437

0.197

n = 468

0.685

 0

31.9 (28.4–35.6) (n = 216)

33.9 (29.4–38.5) (n = 148)

32.5 (28.3–36.9) (n = 152)

 0.1 > 1

33.5 (30.0–37.2) (n = 227)

31.4 (27.0–35.9) (n = 137)

32.5 (28.3–36.9) (n = 152)

  ≥ 1

34.6 (31.0–38.3) (n = 234)

34.8 (30.3–39.5) (n = 152)

35.0 (30.7–39.6) (n = 164)

DBS score

n = 677

n = 437

0.039*

n = 468

0.001*

 0

50.2 (46.4–54.1) (n = 340)

53.8 (49.0–58.5) (n = 235)

54.1 (49.4–58.6) (n = 253)

 0.1 > 1

30.6 (27.1–34.2) (n = 207)

27.9 (23.8–32.4) (n = 122)

30.1 (26.0–34.5) (n = 141)

  ≥ 1

19.2 (16.2–22.2) (n = 130)

18.3 (14.8–22.3) (n = 80)

15.8 (12.6–19.4) (n = 74)^b